M&A Deal Summary |
|
|---|---|
| Date | 2018-07-17 |
| Target | EpiBiome - Bacteriophage Platform |
| Sector | Life Science |
| Buyer(s) | Locus Biosciences |
| Sellers(s) | EpiBiome |
| Deal Type | Divestiture |
SEARCH BY
Locus Biosciences, Inc. is a biotechnology company developing CRISPR Cas3-engineered precision antibacterial products. Its novel approach leverages an adaptive immune system present in many bacteria called the CRISPR-Cas system to engineer bacteriophages that precisely kill target bacteria while leaving non-targeted beneficial bacteria unharmed.
| DEAL STATS | # |
|---|---|
| Overall | 1 of 1 |
| Sector: Life Science M&A | 1 of 1 |
| Type: Divestiture M&A Deals | 1 of 1 |
| State: California M&A | 1 of 1 |
| Country: United States M&A | 1 of 1 |
| Year: 2018 M&A | 1 of 1 |
EpiBiome, Inc. is a microbiome engineering company researches on bacterial populations and to develop effective and sustainable FDA-approved therapies to combat infectious diseases in humans and in agriculture without the use of shared-class antibiotics.
| DEAL STATS | # |
|---|---|
| Overall | 1 of 1 |
| Sector: Life Science M&A | 1 of 1 |
| Type: Divestiture M&A Deals | 1 of 1 |
| State: California M&A | 1 of 1 |
| Country: United States M&A | 1 of 1 |
| Year: 2018 M&A | 1 of 1 |
